征服者恐惧- hk:一项基于元认知的随机对照试验,在中国癌症幸存者中对癌症复发的恐惧进行人工干预。

IF 17.4 1区 医学 Q1 PSYCHIATRY
Danielle Wing Lam Ng, Rachel Ng, Ceci Guo, Julia Chan, Richard Fielding, Julia Wei Chun Tang, Wylie Wai Yee Li, Chi Chung Foo, Ava Kwong, Simon Siu-Man Ng, Dacita Suen, Sara Fung, Oi Kwan Chun, Karen Kar Loen Chan, Amy Tien Yee Chang, Phyllis Butow, Wendy Wing Tak Lam
{"title":"征服者恐惧- hk:一项基于元认知的随机对照试验,在中国癌症幸存者中对癌症复发的恐惧进行人工干预。","authors":"Danielle Wing Lam Ng, Rachel Ng, Ceci Guo, Julia Chan, Richard Fielding, Julia Wei Chun Tang, Wylie Wai Yee Li, Chi Chung Foo, Ava Kwong, Simon Siu-Man Ng, Dacita Suen, Sara Fung, Oi Kwan Chun, Karen Kar Loen Chan, Amy Tien Yee Chang, Phyllis Butow, Wendy Wing Tak Lam","doi":"10.1159/000547888","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fear of cancer recurrence (FCR) is a prominent clinical issue among cancer survivors. This study evaluated the effectiveness of the culturally adapted ConquerFear-HK intervention in reducing FCR among Chinese cancer survivors, compared to standard survivorship care.</p><p><strong>Methods: </strong>This assessor-masked, two-arm parallel randomized controlled trial, was conducted from June 2021 to February 2024. Cantonese- or Mandarin-speaking Chinese cancer survivors scoring ≥13 on the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) were randomized to either ConquerFear-HK, focusing on attention training, metacognition modification, acceptance, appropriate monitoring behaviour, and goal setting or active control providing standardized, multidisciplinary survivorship care. Primary outcome was changes in FCR assessed by FCRI at prior randomization, immediately post-intervention (T1), 3 months (T2), and 6 months (T3) post-intervention. Intention-to-treat analyses using linear mixed modelling compared outcome changes across time points. This trial was registered at <ext-link ext-link-type=\"uri\" xlink:href=\"http://ClinicalTrials.gov\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">ClinicalTrials.gov</ext-link> (NCT04568226).</p><p><strong>Results: </strong>Of the 175/220 (79.5%) participants recruited, 89 were randomized to ConquerFear-HK and 86 to control. Significant greater FCRI reductions were observed in ConquerFear-HK at T1 (mean difference = -10.66; 95% CI:-20.15, -1.16) and T2 (mean difference = -12.00; 95% CI:-21.90, -2.11) vs. the control (g = 0.33-0.36). No significant between-group differences were found at T3.</p><p><strong>Conclusion: </strong>ConquerFear-HK demonstrates promising short-term (3-month) improvements in FCR among Chinese cancer survivors; however, no sustained benefits were found at 6 months. Possible explanations include the high attrition at 6-month follow-up, a potential early ceiling effect, unconscious therapist bias, or an accelerated adaptation effect in the intervention arm that was achieved later by the control group.</p>","PeriodicalId":20744,"journal":{"name":"Psychotherapy and Psychosomatics","volume":" ","pages":"1-17"},"PeriodicalIF":17.4000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ConquerFear-HK: A Randomized Controlled Trial of a Metacognition-Based, Manualized Intervention for Fear of Cancer Recurrence among Chinese Cancer Survivors.\",\"authors\":\"Danielle Wing Lam Ng, Rachel Ng, Ceci Guo, Julia Chan, Richard Fielding, Julia Wei Chun Tang, Wylie Wai Yee Li, Chi Chung Foo, Ava Kwong, Simon Siu-Man Ng, Dacita Suen, Sara Fung, Oi Kwan Chun, Karen Kar Loen Chan, Amy Tien Yee Chang, Phyllis Butow, Wendy Wing Tak Lam\",\"doi\":\"10.1159/000547888\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Fear of cancer recurrence (FCR) is a prominent clinical issue among cancer survivors. This study evaluated the effectiveness of the culturally adapted ConquerFear-HK intervention in reducing FCR among Chinese cancer survivors, compared to standard survivorship care.</p><p><strong>Methods: </strong>This assessor-masked, two-arm parallel randomized controlled trial, was conducted from June 2021 to February 2024. Cantonese- or Mandarin-speaking Chinese cancer survivors scoring ≥13 on the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) were randomized to either ConquerFear-HK, focusing on attention training, metacognition modification, acceptance, appropriate monitoring behaviour, and goal setting or active control providing standardized, multidisciplinary survivorship care. Primary outcome was changes in FCR assessed by FCRI at prior randomization, immediately post-intervention (T1), 3 months (T2), and 6 months (T3) post-intervention. Intention-to-treat analyses using linear mixed modelling compared outcome changes across time points. This trial was registered at <ext-link ext-link-type=\\\"uri\\\" xlink:href=\\\"http://ClinicalTrials.gov\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\">ClinicalTrials.gov</ext-link> (NCT04568226).</p><p><strong>Results: </strong>Of the 175/220 (79.5%) participants recruited, 89 were randomized to ConquerFear-HK and 86 to control. Significant greater FCRI reductions were observed in ConquerFear-HK at T1 (mean difference = -10.66; 95% CI:-20.15, -1.16) and T2 (mean difference = -12.00; 95% CI:-21.90, -2.11) vs. the control (g = 0.33-0.36). No significant between-group differences were found at T3.</p><p><strong>Conclusion: </strong>ConquerFear-HK demonstrates promising short-term (3-month) improvements in FCR among Chinese cancer survivors; however, no sustained benefits were found at 6 months. Possible explanations include the high attrition at 6-month follow-up, a potential early ceiling effect, unconscious therapist bias, or an accelerated adaptation effect in the intervention arm that was achieved later by the control group.</p>\",\"PeriodicalId\":20744,\"journal\":{\"name\":\"Psychotherapy and Psychosomatics\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":17.4000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychotherapy and Psychosomatics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547888\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychotherapy and Psychosomatics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547888","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

癌症复发恐惧(Fear of cancer recurrence, FCR)是癌症幸存者中一个突出的临床问题。本研究评估了文化适应性的征服者恐惧- hk干预在降低中国癌症幸存者的FCR方面的有效性,与标准的幸存者护理相比。方法:在2021年6月至2024年2月期间进行了一项评估器屏蔽的双臂平行随机对照试验。在癌症复发恐惧量表短表(FCRI-SF)中得分为bb0 - 13分的粤语或普通话中国癌症幸存者被随机分配到征服者恐惧- hk,重点是注意训练,元认知修正,接受,适当的监测行为和目标设定;或者主动控制,提供标准化的,多学科的生存护理。主要结局是FCRI在随机化前、干预后立即(T1)、干预后3个月(T2)和干预后6个月(T3)评估的FCR变化。使用线性混合模型的意向治疗分析比较了不同时间点的结果变化。该试验已在ClinicalTrials.gov注册(NCT04568226)。结果:在招募的175/220(79.5%)参与者中,89人随机分配到征服者恐惧- hk组,86人随机分配到对照组。在T1时,征服者恐惧- hk组观察到显著更大的FCRI降低(平均差=-10.66;95% CI:-20.15, -1.16)和T2(平均差异=-12.00;95%置信区间:-21.90,-2.11),与控制(g = 0.33 - -0.36)。T3组间无明显差异。结论:征服者恐惧- hk在中国癌症幸存者中显示出有希望的短期(3个月)改善FCR;然而,在6个月时没有发现持续的益处。可能的解释包括6个月随访期间的高损耗率,潜在的早期天花板效应,无意识的治疗师偏见,或干预组后来由对照组实现的加速适应效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
ConquerFear-HK: A Randomized Controlled Trial of a Metacognition-Based, Manualized Intervention for Fear of Cancer Recurrence among Chinese Cancer Survivors.

Introduction: Fear of cancer recurrence (FCR) is a prominent clinical issue among cancer survivors. This study evaluated the effectiveness of the culturally adapted ConquerFear-HK intervention in reducing FCR among Chinese cancer survivors, compared to standard survivorship care.

Methods: This assessor-masked, two-arm parallel randomized controlled trial, was conducted from June 2021 to February 2024. Cantonese- or Mandarin-speaking Chinese cancer survivors scoring ≥13 on the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) were randomized to either ConquerFear-HK, focusing on attention training, metacognition modification, acceptance, appropriate monitoring behaviour, and goal setting or active control providing standardized, multidisciplinary survivorship care. Primary outcome was changes in FCR assessed by FCRI at prior randomization, immediately post-intervention (T1), 3 months (T2), and 6 months (T3) post-intervention. Intention-to-treat analyses using linear mixed modelling compared outcome changes across time points. This trial was registered at ClinicalTrials.gov (NCT04568226).

Results: Of the 175/220 (79.5%) participants recruited, 89 were randomized to ConquerFear-HK and 86 to control. Significant greater FCRI reductions were observed in ConquerFear-HK at T1 (mean difference = -10.66; 95% CI:-20.15, -1.16) and T2 (mean difference = -12.00; 95% CI:-21.90, -2.11) vs. the control (g = 0.33-0.36). No significant between-group differences were found at T3.

Conclusion: ConquerFear-HK demonstrates promising short-term (3-month) improvements in FCR among Chinese cancer survivors; however, no sustained benefits were found at 6 months. Possible explanations include the high attrition at 6-month follow-up, a potential early ceiling effect, unconscious therapist bias, or an accelerated adaptation effect in the intervention arm that was achieved later by the control group.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Psychotherapy and Psychosomatics
Psychotherapy and Psychosomatics 医学-精神病学
CiteScore
29.40
自引率
6.10%
发文量
46
期刊介绍: Psychotherapy and Psychosomatics is a reputable journal that has been published since 1953. Over the years, it has gained recognition for its independence, originality, and methodological rigor. The journal has been at the forefront of research in psychosomatic medicine, psychotherapy research, and psychopharmacology, and has contributed to the development of new lines of research in these areas. It is now ranked among the world's most cited journals in the field. As the official journal of the International College of Psychosomatic Medicine and the World Federation for Psychotherapy, Psychotherapy and Psychosomatics serves as a platform for discussing current and controversial issues and showcasing innovations in assessment and treatment. It offers a unique forum for cutting-edge thinking at the intersection of medical and behavioral sciences, catering to both practicing clinicians and researchers. The journal is indexed in various databases and platforms such as PubMed, MEDLINE, Web of Science, Science Citation Index, Social Sciences Citation Index, Science Citation Index Expanded, BIOSIS Previews, Google Scholar, Academic Search, and Health Research Premium Collection, among others.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信